Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off‐label for the treatment of nondiabetic or diabetic patients with biopsy‐proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side effects have limited its use for NASH. Pioglitazone i...

Full description

Bibliographic Details
Main Authors: Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila DeWitt
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1723

Internet

https://doi.org/10.1002/hep4.1723

Similar Items